Under construction – not a live service
Sign in
Taking people in United StatesNo phase

Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain

Key facts

Where
Ann Arbor, Atlanta, Chicago, Durham, Greenville, Hartford, Los Angeles, Mobile, New York, Newark, Pittsburgh, Richmond, and Rochester, United StatesSee the 14 sites

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 16 and 39 years old?

Source: NCT06374238, who can take part

Where in United States

  • The Regents of the University of MichiganAnn Arbor, United StatesTaking people
  • Children's Healthcare of AtlantaAtlanta, United StatesTaking people
  • Ann and Robert H. Lurie Children's Hospital of ChicagoChicago, United StatesTaking people
  • Wake Forest Baptist HospitalDurham, United StatesTaking people
  • East Carolina University Health Medical CenterGreenville, United StatesTaking people
  • Connecticut Children's Medical CenterHartford, United StatesTaking people
  • UCLA Mattel Children's Hospital Ronald Reagan HospitalLos Angeles, United StatesTaking people
  • University of South Alabama Medical CenterMobile, United StatesTaking people
  • Weil Cornell Medical CollegeNew York, United StatesTaking people
  • Rutgers New Jersey Medical SchoolNewark, United StatesTaking people
  • UPMC Children's Hospital of PittsburghPittsburgh, United StatesTaking people
  • UPMC University of Pittsburgh Classical Hematology Adult ClinicPittsburgh, United StatesTaking people
  • Virginia Commonwealth UniversityRichmond, United StatesTaking people
  • University of Rochester Medical CenterRochester, United StatesTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University of Pittsburgh
Trial code
NCT06374238
Record updated
8 October 2026
Original description
The study, known as the Peer suppoRt for adolescents and Emerging adults with Sickle cell pain: promoting ENgagement in Cognitive behavioral thErapy (PRESENCE), aims to determine the effectiveness of digital CBT in reducing pain, opioid use, and healthcare utilization among AYAs with SCD. It also seeks to understand the role of personalized peer support in enhancing engagement and outcomes of digital CBT interventions.Read full original descriptionShow less

Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain: Promoting Engagement in Cognitive Behavioral Therapy

The study, known as the Peer suppoRt for adolescents and Emerging adults with Sickle cell pain: promoting ENgagement in Cognitive behavioral thErapy (PRESENCE), aims to determine the effectiveness of digital CBT in reducing pain, opioid use, and healthcare utilization among AYAs with SCD. It also seeks to understand the role of personalized peer support in enhancing engagement and outcomes of digital CBT interventions.

By leveraging existing infrastructure for delivering virtual peer support interventions, tailored digital CBT programs for individuals with SCD, and partnerships with CBOs, the study aims to provide valuable insights into the feasibility and effectiveness of digital CBT as a pain management strategy for this vulnerable population.

Inclusion: Aged 16 to 39 years of age at time of enrollment; Sickle Cell Disease diagnosis of any genotype based on referral or documentation; Reports chronic pain (≥4 days/week for past 3 months or more) OR A) Being prescribed pain medication to be taken (≥4 days/week for past 3 months or more) OR B) Taking pain medication (≥4 days/week for past 3 months or more) OR C) Receiving non-pharmaceutical pain treatment (≥4 days/week for past 3 months or more); Access to an iOS or Android mobile device with internet access.

Exclusion: Prior hematopoietic stem cell transplant for sickle cell disease; Unable to speak or read English; Not living in the United States throughout enrollment and duration of the study period.

ClinicalTrials.gov NCT06374238